The disruptions caused by COVID-19 have complicated both the initiation and execution of clinical trials involving therapies targeting amyotrophic lateral sclerosis (ALS). Read our experts’ perspectives on how to flex during this global pandemic.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
Tom Babic, MD, PhD
Vice President, Scientific Solutions, Neuroscience
Barry Dussault
Executive Director, Project Management, Franchise Area Lead, Pain
